Dr Ben Tran speaks to ecancer about a real-world study which evaluated outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) who required treatment after lutetium-177 vipivotide tetraxetan (Lu177).

Among 743 patients treated with Lu177, 161 (22%) initiated subsequent therapy, with more than 40 different treatment regimens identified.

The most common regimens were cabazitaxel, cabazitaxel plus carboplatin, and enzalutamide, and about 50% of patients received chemotherapy-based treatment.

Median overall survival from the start of post-Lu177 therapy was 8.0 months overall, with 13.5 months in pre-taxane patients and 6.8 months in post-taxane patients.

Poor performance status (ECOG ≥2) and shorter duration of prior Lu177 treatment (<180 days) were associated with significantly worse survival.

Overall, treatment selection after Lu177 was highly variable and associated with short treatment duration and limited survival, highlighting the unmet need for more effective therapies in the post-Lu177 mCRPC setting.